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Abstract: Pinnatoxins (PnTXs) are emerging neurotoxins that were discovered about 30 years ago.
They are solely produced by the marine dinoflagellate Vulcanodinium rugosum, and may be transferred
into the food chain, as they have been found in various marine invertebrates, including bivalves.
No human intoxication has been reported to date although acute toxicity was induced by PnTxs in
rodents. LD50 values have been estimated for the different PnTXs through the oral route. At sublethal
doses, all symptoms are reversible, and no neurological sequelae are visible. These symptoms are
consistent with impairment of central and peripheral cholinergic network functions. In fact, PnTXs
are high-affinity competitive antagonists of nicotinic acetylcholine receptors (nAChRs). Moreover,
their lethal effects are consistent with the inhibition of muscle nAChRs, inducing respiratory distress
and paralysis. Human intoxication by ingestion of PnTXs could result in various symptoms observed
in episodes of poisoning with natural nAChR antagonists. This review updates the available data on
PnTX toxicity with a focus on their mode of action on cholinergic networks and suggests the effects
that could be extrapolated on human physiology.
Keywords: pinnatoxins; cyclic imines; Vulcanodinium rugosum; nicotinic acetylcholine receptors; acute
neurotoxicity; human intoxication; myasthenia gravis
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1. Introduction
1.1. Ecological Aspects
The name pinnatoxin (PnTX) originates from Pinna attenuata, a bivalve mollusk from the South
China Sea in which these toxic compounds were first collected [1]. Pinnatoxin A (PnTX-A), isolated
from the mother-of-pearl Pinna muricata harvested in the Japanese island of Okinawa, was the first
PnTX with structural elucidation [2]. About a decade ago, a dinoflagellate producing PnTX-E and -F
was isolated—but not identified—from water samples of the shallow harbor of Rangaunu in northern
New Zealand [3]. These toxins produced neurotoxicity to mice. They belong to the group of cyclic
imines, neurotoxic molecules included in the lipophilic toxin group [4]. To date, the dinoflagellate
Vulcanodinium rugosum, collected from lagoon water samples in southern France, was identified in 2009
as the sole producer of PnTXs [5]. This identification was subsequent to an investigation following an
atypical result from the regulatory monitoring of lipophilic toxins in shellfish, showing that mussel
extracts from the Ingril lagoon (Mediterranean Sea, France) induced unexpected neurotoxic effects in a
mouse bioassay [6]. This observed toxicity was considered unusual and inconsistent with the toxic
effects induced by the other known lipophilic toxins [7]. In addition, no microalgal species known to
produce neurotoxins was observed in the water samples.
1.2. Chemistry of PnTXs
PnTXs belong to the group of cyclic and macrocyclic imines including about 40 different
molecules. The acylated esters produced by shellfish detoxification metabolism should also be
considered [4]. The cyclic imine group includes toxins with various backbone features: Prorocentrolides,
spiro-prorocentrimine, gymnodimines, spirolides, PnTXs, pteriatoxins (PtTX), and portimine. PnTXs
and PtTXs share several structural similarities and, among the other compounds, spirolides are
structurally the closest to PnTXs [8]. These molecules were found in both plankton and shellfish
extracts—mostly bivalves. In shellfish, esterified forms resulting from the metabolic transformation of
PnTxs through the formation of acyl esters with fatty acids were also detected [9].
PnTXs are characterized by a central invariable backbone with four external substituents R1 to
R4 (Figure 1A). This central backbone is an amphoteric macrocyclic structure composed of several
rings of type 6,7-spiro (A and G rings), 5,6-bicyclo (bridged E and F rings), or acetal 6,5,6-trispiro (B, C
and D rings) [10]. Their molecular weight is about 700 g.mol−1 (Figure 1B). The metabolism of PnTXs
and PtTXs in shellfish was investigated from environmental samples collected at Franklin Harbor,
Australia, with structural toxin elucidation by NMR [8]. PnTX-B, -C, and -D and PtTX-A, -B, and -C
were suggested as metabolites of PnTX-E, -F, and -G.
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Figure 1. Pinnatoxin (PnTX) chemical features. (A) General backbone of PnTXs. Rings in red. The 
group substitutions R1 to R4 that differ among PnTXs are indicated. (B) Chemical structure, formula, 
and external radicals of PnTX. MW = molecular weight. 
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symptoms appear a few minutes after oral or intraperitoneal (i.p) administration [11]. As such, PnTXs 
can be categorized as fast-acting toxins, like other cyclic imines. Neurotoxic symptoms lead to death 
by respiratory arrest. Signs of toxicity include decreased mobility—sometimes preceded by a very 
active phase just after administration—hind limb paralysis, and breathing difficulties [11]. Tremors 
and jumps are also reported [12]. The lethal dose 50% (LD50) in mice varies according to the PnTX 
analogue and the route of administration. Orally, LD50 ranges between 25 and 2800 μg/kg bw for 
PnTX-F and PnTX-E, respectively (Table 1). Toxicity varies as follows: PnTX-F > PnTX-G ~ PnTX-H >> 
PnTX-E. 
  
Figure 1. Pinnatoxin (PnTX) chemical features. (A) General backbone of PnTXs. Rings in red. The
group substitutions R1 to R4 that differ among PnTXs are indicated. (B) Chemical structure, formula,
and external radicals of PnTX. MW = molecular weight.
2. Acute Toxicity
2.1. In Vivo: Symptoms Observed in Mice
Several studies have reported the in vivo effects of purified PnTXs, producing a coherent set of
information concerning the acute toxicity of PnTXs. The toxicity in mice occurs rapidly, since the
symptoms appear a few minutes after oral or intraperitoneal (i.p) administration [11]. As such, PnTXs
can be categorized as fast-acting toxins, like other cyclic imines. Neurotoxic symptoms lead to death by
respiratory arrest. Signs of toxicity include decreased mobility—sometimes preceded by a very active
phase just after administration—hind limb paralysis, and breathing difficulties [11]. Tremors and
jumps are also reported [12]. The lethal dose 50% (LD50) in mice varies according to the PnTX analogue
and the route of administration. Orally, LD50 ranges between 25 and 2800 µg/kg bw for PnTX-F and
PnTX-E, respectively (Table 1). Toxicity varies as follows: PnTX-F > PnTX-G ~ PnTX-H >> PnTX-E.
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Table 1. Acute in vivo toxicity of PnTXs in mice (oral route). CI95: 95% confidence interval. ND: Not
determined. *Purity verified by NMR (% not mentioned). MTD: Maximum tolerated dose (dose at
which neither mortality was observed, nor clinical signs were evident).
Toxin and %
Purity
Route of
Administration
and Conditions
LD50
(µg/kg pc)
MTD
(µg/kg pc) References
PnTX E*
Per os 2800
600 [11]Fed mice CI95: 2380–3000
PnTX F*
Per os 25.0 9,9
[11]
Fed mice CI95: 19.1–35.1
Per os 29.9
ND16 h fasted mice CI95: 25–32
Voluntary intake 50.0 16,0
Fed mice CI95: 39.4–62.8
Voluntary intake 50.0
NDFed mice CI95: 37.9–71.5
Voluntary intake 50.0
ND16 h fasted mice CI95:37.9–71.5
Voluntary intake 77.0
ND16h fasted mice CI95: ND
Voluntary intake 50.0
ND16h fasted mice CI95: 39.4–62.8
PnTX-G*
Per os 150.0
75 [11]Fed mice CI95:105–100
PnTX-G
(100%)
Per os 208.0
120 [12]3 h fasted mice CI95: 155–281
PnTX-G*
Voluntary intake 400.0
153 [11]Fed mice CI95: 380–470
PnTX H*
Per os 163.0
ND [13]CI95: 139–175
By i.p route, LD50 values range between 13 and 115 µg/kg bw, for the PnTX-F and PnTX-A,
respectively, and the toxicity can be ranked as follows: PnTX-F > PnTX-G > PnTX-E > PnTX-H >
PnTX-A [11,13,14].
At sub-lethal doses, mice recover quickly and completely from PnTX administration without
functional consequence [8,11,13]. In fact, the same signs of intoxication are observed but breathing
returned to normal within one hour. A lethargic state with piloerection is also described before
complete recovery 2 to 3 h after PnTX administration [11]. No macroscopic organ abnormalities are
observed at necropsy [8,11,13]. The potent neurotoxicity of PnTXs and associated symptoms led
authors to investigate their effects on skeletal muscle contraction. A recent study clearly shows that
synthetic PnTX-A and -G, when injected in vivo in the mouse tail muscle at nanomolar concentrations
(nmol of PnTX per kg of mouse), caused a dose- and time-dependent reduction of the nerve-evoked
compound muscle action potential (CMAP), which reflects the number of muscle fibers that are able
to trigger an action potential upon nerve stimulation [15]. The block of neuromuscular transmission
in vivo by PnTX-A and -G is reversible in 6 to 8 h.
Methanolic extracts of V. rugosum cultures have been also challenged through oral and i.p routes
in mice [3,12]. They exhibit a similar acute toxicity to PnTXs with fatal outcome by respiratory arrest.
Symptoms preceding death included piloerection, prostration, hypothermia, paralysis of the lower
limbs, abdominal breathing, and cyanosis. Death occurred within minutes after mice exposure to
the extracts. Post-mortem observations revealed redness in the non-glandular stomach and jejunum
together with fluid accumulation in the jejunum [12].
Mar. Drugs 2019, 17, 425 5 of 13
2.2. In Vitro Muscle Paralysis
The effects of PnTXs have been also evaluated in isolated rat hemidiaphragms, in order to
understand the acute respiratory effects observed in vivo [16]. PnTX-F alone (130–520 nM) or mixed
with PnTX-E inhibit the nerve impulse-induced CMAP, without affecting it when evoked by direct
muscle stimulation. Neostigmine (8 µM), a well-used inhibitor of acetylcholinesterase, is not able to
reverse the inhibition of the CMAP caused by PnTX-F (260 nM) [16]. The PnTX-evoked inhibition of
muscle excitability is correlated with the inhibition of muscle contraction [15,16]. Indeed, PnTX-E, -F,
and -G drastically reduce muscle contraction of the rat hemi-diaphragm (IC50 from 11 to 53 nM). PnTX-F
and -G reduce the amplitude of both miniature end-plate potentials (mEPPs)—corresponding to the
spontaneous quantal ACh release—and end-plate potentials (EPPs)—corresponding to the evoked
quantal ACh release in rat phrenic-cut-hemidiaphragm muscle, with an extracellular medium having a
reduced K+ concentration [17]. These results, together with those obtained on mouse neuromuscular
junctions showing that ACh-evoked potentials, mEPPs, and EPPs were reduced in amplitude and
blocked by PnTX-A and PnTX-G in a normal extracellular medium, indicate that PnTXs block the
interaction between ACh and its muscle nAChRs at the endplate [15]. Such blockade of neuromuscular
transmission in vitro can explain the ability of PnTXs to block the CMAP evoked by motor nerve
stimulation in vivo. In addition, preliminary in ovo data indicate an inhibitory effect of PnTX-A on the
skeletal development and the muscular apparatus of the chicken embryo [18].
2.3. In Vitro: Molecular and Cellular Targets
2.3.1. Nicotinic Acetylcholine Receptors (nAChRs)
The nAChRs, which are the sole targets of PnTXs, are ionotropic receptors acting as cation channels.
They are physiologically activated by the neurotransmitter acetylcholine (ACh), in the peripheral and
the central nervous system, and can be exogenously activated by nicotine [19]. They are also expressed
in non-neuronal tissues [20]. Cholinergic networks implicate nAChRs in different synapses, where
they are expressed at presynaptic or postsynaptic sites in order to finetune the neurotransmitter release
process, or to activate the post-synaptic cell [21].
Several types of nAChRs have been characterized. Their differences were initially evidenced by
the selectivity of various ligands towards the peripheral vegetative nervous system and the skeletal
muscle fibers. The discrepancies in affinity are directly linked to the subunit composition of the
receptors, some being homopentamers while others are heteropentamers. As of today, 16 subunits
are identified: α1-10, β1-4, γ, δ, and ε – the α8 subunit does not exist in the mammalian nervous
system [22]. About 10 different subunit compositions, characteristic of muscular or neuronal expression
(Figure 2), have been described.
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[19,20]). (B) Mode of action of PnTXs at the neuromuscular junction. The toxins bind to the sites where 
it normally binds on the nAChR expressed at the surface of the endplate muscle membrane, thus 
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The nAChRs extracted from the Torpedo electric organ (Torpedo marmorata), where their density 
is high, have been used for pharmacological and physiological characterization [23]. In humans, 
muscle nAChRs are heteropentamers of type (α1)2β1γδ—in the embryo—or (α1)2β1εδ—in the adult 
[24]. These receptors are activated by the binding of two ACh molecules to distinct sites, at the α1-γ, 
α1-δ, or α1-ε interface. The release of ACh by a motor nerve terminal allows the activation of muscle 
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Figure 2. PnTXs act as competitive antagonists of nicotinic acetylcholine receptors (nAChRs). (A)
Central (upper) and peripheral (lower) nAChRs, as a function of their subunit composition. Some
nAChRs are exclusively present in the CNS or in the PNS, for instance the ganglia of the autonomous
system. Others, like α7 homopentamers or α3β2 heteropentamers, are expressed in both. Note
that only a few of the existing nAChRs are represented (α7β2, α4β2 for example are not presented,
see [19,20]). (B) Mode of action of PnTXs at the neuromuscular junction. The toxins bind to the sites
where it normally binds on the nAChR expressed at the surface of the endplate muscle membrane,
thus impairing the opening of the cationic pore. When the receptor is inhibited, it cannot promote the
depolarization of the endplate membrane, which impairs the generation of a muscle action potential
and thereby the initiatio of muscle contraction.
Muscle nAChRs
The nAChRs extracted from the Torpedo electric organ (Torpedo marmorata), where their density is
high, have been used for pharmacological an physiological characterization [23]. In humans, muscle
nAChRs are heteropentamers of type (α1)2β1γδ—in t e embryo—or (α1)2β1εδ—in the adult [24].
These receptors are activated by the binding of two ACh molecules to distinct sites, at the α1-γ, α1-δ, or
α1-ε interface. The release of ACh by a motor nerve terminal allows the activation of muscle nAChRs.
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Their opening induces membrane depolarization, which favors the opening of the skeletal muscle
voltage-gated Na+ channels (Nav1.4) and the generation of muscle action potentials, which trigger
muscle fiber contraction ([25], Figure 2).
Neuronal nAChRs
They are heteropentameric receptors combining two α subunits (α2 to α10, but no α8) and three
β subunits (β2 to β4), or homopentameric with the α7 subunit. Heteropentamers possess two ACh
binding sites, while homopentamers have five. In the central nervous system (CNS), α4, α6, α7, β2,
and β3 are the predominant subunits [19]. In the peripheral nervous system (PNS), nAChRs within
sympathetic and parasympathetic ganglia express abundantly α3, α5, α7, and β2 and β4 subunits
(Figure 2). Activation of central nAChRs results in the opening of the central cation channel and the
influx of Na+ and Ca2+ ions. This post-synaptic membrane depolarization can lead to the genesis of a
neuronal action potential, which ends in the release of neurotransmitter at the nerve terminal.
2.3.2. PnTXs Target nAChRs
Like other cyclic imines, PnTXs are competitive antagonists of nAChRs. They bind to ACh binding
sites competitively, thus preventing the opening of the pore. The reversibility of this effect depends on
the subtypes of nAChR. PnTXs share a common mode of action, and it seems very unlikely that some
PnTXs analogues may act differently [26]. PnTXs unambiguously target muscle_type nAChRs causing
a concentration-dependent block of muscle contraction induced by nerve stimulation. PnTX-A, -E, -F,
and -G block nerve-impulse-evoked muscle contraction, without affecting muscle contraction caused
by direct muscle stimulation [15,17]. The muscle paralysis is due to the antagonistic effect of PnTXs on
nAChRs (Figure 2).
In fact, PnTX A and G reversibly inhibit nAChRs, but this inhibitory effect is different in muscular
and neuronal receptors and may be modulated by the subunit composition of these receptors [27]. These
conclusions have been drawn from in vitro electrophysiology experiments using either heterologous
expression of nAChRs (cDNA or mRNA) or microtransplantation of purified membranes from the
electric organ of Torpedo (Torpedo marmorata) in Xenopus oocytes using voltage-clamp techniques.
To deepen the knowledge on the mode of action of PnTXs, competitive binding and high-affinity
radioligand displacement assays were performed on HEK-293 cells transfected with different human
or chicken receptor subtypes. Receptors tested were α7 (neuronal), α4β2 and α3β2 (neuronal), and
(α1)2β1γδ (Torpedo) [4] (Figure 2). Both binding and electrophysiology assays showed that PnTXs
bind to muscular and neuronal nAChRs with high affinity, and with a rank order of potency as follows:
Muscular receptor (Torpedo) > α7 (human) > α4β2 ~ α3β2. In addition, PnTX selectivity for nAChRs
has been demonstrated by testing, using competitive binding assays, on more than 40 other receptors,
transporters, and ion channels [26]. In conclusion, muscle nAChRs are not the only targets of PnTXs,
but their blocking is enough to experimentally induce a lethal effect. Electrophysiology and binding
assays show that these toxins bind to muscle and neuronal nAChRs. Most of the mouse symptoms
induced by acute PnTXs exposure can be explained by a blockade of muscle nAChRs.
3. Possible Effects to Humans by Extrapolation of Experimental Data
No case of human poisoning due to PnTXs has been reported to date. In China, a human intoxication
was first related to the presence of PnTX-A, but finally other contaminants were incriminated [1]. More
recently, a Vulcanodinium rugosum bloom was identified in Cuba (Cienfuegos Bay), and suspected to
have caused skin lesions of swimmers, but PnTXs were not assessed [28]. This observation could stem
from the cytotoxicity of one or more of the high number of compounds produced by V. rugosum, which,
for most of them, remain unidentified [29]. However, it could also be due to PnTXs, since the presence
of non-neuronal nAChRs is well documented in keratinocytes [30]. The description of clinical effects
observed in humans after exposure to drugs or natural toxins sharing a comparable pharmacology
to PnTXs is briefly reviewed hereinafter. Alongside, some pathologies and their symptomatology,
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which could be expected after exposure to PnTXs, are outlined based on both in vivo and in vitro
toxicological studies.
3.1. Clinical Effects of nAChR Antagonists
As mentioned previously, PnTXs are nAChR antagonists, targeting peripheral skeletal muscle-type
(α1)2βγδ and (α1)2βεδ nAChRs of the neuromuscular junction, ganglionicα3β2, α3β4, andα7 nAChRs
of autonomic ganglia, and the central nervous systemα4β2,α7,α3β2, andα4α6β2 nAChR. Antagonists
of nAChRs, acting on skeletal muscle or autonomous ganglia, are named muscle relaxants or autonomic
agents, respectively, and have been extensively studied. Their main effects are described in the
following sections.
3.1.1. Skeletal Muscle Relaxants
The reversible antagonists of muscle nAChRs are used in therapeutics to induce a relaxation
of skeletal muscles during surgery intervention procedures. These molecules do not cross the
blood–brain barrier. There are two types of muscle relaxants: Depolarizing blocking drugs (DBDs) and
non-depolarizing blocking drugs (NDBDs) [31].
The DBDs includes succinylcholine (suxamethonium), which induces a sustained depolarization
of the skeletal muscle fibers and desensitizes nAChRs. It is used in surgical anesthesia due
to a fast and brief duration of action. DBDs reproduce the effects induced by high doses of
ACh without degradation by the synaptic acetylcholinesterase. NDBDs are synthetic molecules,
which mimic d-tubocurarine, the main component of curare. This plant toxin has been used as
a molecular template for the synthesis of other muscle relaxants. They can be divided in two
groups, aminosteroids (pancuronium, vecuronium rocuronium, pipuronium) and benzylisoquinolines
(atracurium cisatracurium, doxacurium, mivacurium) [31]. In fact, they act as competitive antagonists,
substituting to ACh on nAChRs. As such, they prevent the opening of the nAChR channel and the
depolarization of muscle fibers. The effects of NBDBs can normally be reversed by the administration
of acetylcholinesterase inhibitor agents, such as neostigmine, as long as some nAChRs remain free for
ACh to bind [31].
Side effects of muscle relaxants partly result from their modulation of the muscle nAChRs as
well as their ganglionic blocking properties. The nature and intensity of these effects vary for each
considered molecule. They mainly affect blood pressure and cardiac rhythm [31].
3.1.2. Autonomic Agents
The autonomic nervous system expresses nAChRs in ganglionic pre- and post-synaptic neurons
(Figure 2). The nAChR antagonists exert an inhibition over both divisions—sympathetic and
parasympathetic—of the autonomic nervous system and their associated biological effectors. Their
global effect is a combination of these inhibitory effects. As such, the observed effect on a given
organ depends on the predominance of its sympathetic or parasympathetic innervation. When
sympathetic tone predominates, its inhibition will be manifested by parasympathetic effects (i.e.,
vasodilatation resulting in low blood pressure i.e., hypotension). Conversely, if the parasympathetic
tone predominates, ganglionic blocking agents cause sympathetic effects (tachycardia, mydriasis,
constipation, urinary retention) [32].
Both natural and synthetic molecules can be used as autonomic drugs, which either activate or
inhibit the functions modulated by the sympathetic or parasympathetic nervous systems [33]. That
includes antihypertensive drugs, such as hexamethonium and mecamylamine [34]. Their therapeutic
use has been limited due to side effects, notably hypotension and tachycardia, possibly accompanied
by seizures in case of overdose [35].
Ingestion of anti-cholinergic autonomous agents leads to the following symptoms after 1 to 6 h:
Vomiting, dry mouth, constipation, mydriasis, accommodation disorders, elevated intraocular pressure,
decreased lachrymal secretion, sinus tachycardia, risk of urinary retention, and acute glaucoma. In
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case of massive intoxication, excitement, mental confusion, hallucination, hyperthermia, coma, and
respiratory depression have been described [36]. Neurotoxicity, sometimes with the development of
motor neuron pathologies, is induced after chronic exposure. In addition, teratogenic effects have been
reported in animals, as well as in young fed with milk from a goat fed with lupine seed-containing
food [37,38].
3.2. Human Diseases and Pntx Exposure: Autonomic Dysfunctions?
The involvement of nAChRs in several human disorders has been established and makes this
receptor an attractive therapeutic target. Whether implicated in channelopathies resulting from
mutations in the nAChR subunit genes, or targeted by autoimmune antibodies, nAChRs are associated
with different pathologies affecting the CNS and the PNS [39]. Autoimmune myasthenia gravis results
from a neuromuscular blockade implicating muscle nAChRs [40,41]. Binding of antibodies to the
receptors results in a decrease in the amplitude of the motor endplate potentials, thus preventing
the rise of muscle action potentials. The loss of functional nAChRs impairs the nerve-evoked
muscle contraction [42,43]. The main symptom of myasthenia is a fluctuating muscle weakness,
aggravated by the effort and improved by rest. First and main manifestations are ocular with
ptosis and diplopia, but in 80% to 90% of patients, after one year of evolution, other areas are
affected, particularly pharyngo-laryngeal muscles and/or limb muscles and/or respiratory muscles.
Myasthenia then generalizes [44,45]. Generally, myasthenia gravis is not accompanied by signs of
autonomic dysfunction.
Autoimmune myasthenia disease could match with a clinical model of PnTX intoxication.
However, autonomic dysfunction may also be the consequence of nAChR blockade by PnTXs
especially in the autonomic ganglia—which control the effector organs—and the adrenal medulla,
which secretes hormones that act on the cardiovascular system. Autonomic dysfunction symptoms
during an experimental exposure to PnTXs were not observed, but we can anticipate that they could
predominate in case of human intoxications. In conclusion, the association of autonomic symptoms
with neuromuscular signs in humans should challenge the clinician on a possible cause of PnTX
intoxication (Table 2). It should, however, be recalled that there are several types of myasthenia, some
without antibodies, of presynaptic origin, the majority of which is of genetic origin. In the following
table, myasthenia refers to the autoimmune disease, in which antibodies block the muscle nAChRs,
paralleling the mode of action of PnTXs. Fatal respiratory distress in humans may not occur as a
result of PnTX exposure, as it is well known that the diaphragm is much more resistant to muscle
blockers—of NBDB type—than other skeletal muscle groups [46].
Table 2. Clinical signs of toxicity in mice and extrapolation in humans.
Clinical Signs of Toxicity in Mice. Anatomical or PhysiologicalSupport Possible Outcome in Humans
Loss of motor activity Neuromuscular junction impairment(skeletal muscles)
Myasthenic syndrome analogous
with the disease myasthenia gravis
Flaccid paralysis caused by curare
Respiratory depression/arrest Neuromuscular junctionimpairment/block (diaphragm)
Respiratory impairment/arrest in
myasthenia and myasthenic crisis
Seizure Central damage via nAChR inhibition
Seizure crisis (impaired GABA
release
or hereditary mutations)
Leg extension Spinal interneuron impairmentCentral impairment
Pyramidal syndrome
Babinski sign
Reversibility if no death occurs
or after prostigmine injection
Removal of the post-synaptic
neuromuscular block
Fluctuation in the degree of
myasthenic syndrome
or temporary removal of the block
with prostigmine
Removal of the curare action
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Table 2. Cont.
Clinical Signs of Toxicity in Mice. Anatomical or PhysiologicalSupport Possible Outcome in Humans
Exophthalmos Increased intraocular pressure Action of suxamethoniumAction of lupin
Hypersalivation, vomiting, diarrhea,
bradycardia, bronchoconstriction,
miosis
Inhibition of neuronal communication
at ganglia synapses
Autonomous agents acting on the
sympathetic nervous system (side
effects). Nicotinic syndrome
Tachycardia, blood hypertension,
mydriasis
Inhibition of neuronal communication
at ganglia synapses
Autonomous agents acting on the
parasympathetic nervous system
(side effects). Muscarinic
syndrome
4. Conclusions
PnTXs are emerging marine biotoxins produced by the dinoflagellate Vulcanodinium rugosum.
Currently, their presence in seafood is not regulated in Europe nor in any other country in the world.
They can be transferred into the food chain: Since 2011, high concentrations of PnTX-G have been
observed in mussels from French lagoon every year at summertime and more recently, PnTX-G and
-A were detected in mussels from the Atlantic coasts of Spain [47]. PnTX intoxications have not been
reported, either because the levels to which consumers were exposed so far were not sufficient to
induce severe symptoms, or because humans may be less sensitive than mice to PnTXs. Differences in
mouse and human nAChRs might be one reason for this putative discrepancy in species sensitivity.
In mice, PnTXs induce acute neurotoxic effects, within a few minutes after ingestion. Clinical
signs of toxicity include decreased mobility, paralysis of the hind legs, tremors, jumps, and breathing
difficulties, leading to death by respiratory arrest at high doses. PnTXs are high-affinity nAChR
antagonists, which may exert deleterious effects in all neuronal and non-neuronal tissues expressing
these receptors. Until now, only acute toxicity studies of PnTXs are available. Further experimental work
is needed and should provide knowledge on how PnTXs interact with cholinergic networks—including
both neuronal and non-neuronal nAChRs—during both acute and chronic exposures. The toxicokinetics
of these toxins and the effects on a broad range of endpoints as a function of the dose and time of
exposure should also be investigated. It is very likely that PnTXs may be able to cross most of the
biological barriers, including intestinal and blood–brain barriers. PnTXs are classified as fast-acting
toxins, which, in case of food poisoning, could provoke deleterious effects on humans. No human
poisonings due to PnTX ingestion have been reported to date. Such intoxications have been well
documented with other phycotoxins, such as domoic acid, ciguatoxins, or paralytic shellfish toxins [48].
In this view, the French Agency for Food, Environmental, and Occupational Health and Safety
recently proposed a provisional acute benchmark value for PnTXs [49]. Based on (i) the clinical
signs of toxicity in mice, (ii) the mode of action of PnTXs as nAChR competitive antagonists, and
(iii) knowledge of drugs and natural toxins with PnTX-related pharmacology, potential symptoms in
humans are proposed here: Muscle weakness (myasthenic-like syndrome), dyspnea, anticholinergic
syndrome, dysautonomia, pyramidal syndrome, and seizures. Awareness of healthcare professionals of
neurological symptoms induced by PnTXs should help to detect potential cases of human intoxication
associated with shellfish consumption.
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